HOOKIPA Pharma Inc (HOOK) Actualités

Form 8-K - Current report

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line...

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line...

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK...

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK...

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with...

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with...

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK...

Form 8-K - Current report

Form 8-K - Current report

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and...

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK...